Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Susceptibilities of Quinolones against Erythromycin- and Tetracycline-Resistant Mycoplasma pneumoniae Isolates

Erythromycin과 tetracycline에 저항성인 Myoplasma pneumoniae의 quinolone계 항생물질에 대한 감수성

  • Chang, Myung-Woong (Department of Microbiology, Kosin University College of Medicine) ;
  • Park, In-Dal (Department of Microbiology, Kosin University College of Medicine) ;
  • Kim, Kwang-Hyuk (Department of Microbiology, Kosin University College of Medicine)
  • 장명웅 (고신대학교 의과대학 미생물학교실) ;
  • 박인달 (고신대학교 의과대학 미생물학교실) ;
  • 김광혁 (고신대학교 의과대학 미생물학교실)
  • Published : 2006.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

The in vitro activities of quinolones were determined with 36 strains of tetracycline- resistant, 39 strains of erythromycin-resistant, 21 strains of both resistant to tetracycline and erythromycin, and 27 strains of both susceptible to tetracycline and erythromycin of the M. pneumoniae isolates which have been isolated and classified in previous studies. The $MIC_{90}$ of moxifloxacin, levofloxacin, sparfloxacin, ofloxacin, ciprofloxacin, amikacin, and clarithromycin against 36 strains of tetracycline-resistant M. pneumoniae isolates were 0.125, 0.39, 0.125, 1.0, 1.0, 15.6, and $1.56\;{\mu}g/ml$, respectively. The $MIC_{90}$ against 39 strains of eryhtromycin-resistant M. pneumoniae isolates were 0.06, 0.39, 0.125, 1.0, 1.0, 15.6, and $25.0\;{\mu}g/ml$, respectively. The $MIC_{90}$ against 21 strains of both resistant to tetracycline and eryhtromycin of M. pneumoniae isolates were 0.125, 0.39, 0.125, 1.0, 1.0, 3.9, and $1.56\;{\mu}g/ml$, respectively. The $MIC_{90}$ against 27 strains of both susceptible to tetracycline and eryhtromycin of M. pneumoniae isolates were 0.125, 0.39, 0.125, 1.0, 1.0, 7.8, and $0.09\;{\mu}g/ml$, respectively. These result suggest that moxifloxacin, levofloxacin, and sparfloxacin of the quinolones might be promising antimicrobial agents for the treatment of tetracycline- and erythromycin-resistant M. pneumoniae infection. However, selection of ofloxacin, ciprofloxacin, and clarithromycin for the treatment of M. pneumoniae infection should be cautious decision with antimycoplasmal susceptibility test.

호흡기 질환 환자로부터 분리된 M. pneumoniae 123 균주를 tetracycline에 저항성인 tetM 유전자만을 가진 36균주, erythromycin에만 저항성 변이를 일으킨 39균주, tetracycline과erythromycin에 저항성인 21균주, erythromycin과 tetracycline에 감수성인 27균주로 나누어 quinolone 제제와 macrolides계 항생제에 대한 감수성 검사를 시험관 희석법으로 실시하여 다음과 같은 결론을 얻었다. Tetracycline에만 저항성인 M. pneumoniae 36균주의 moxifloxacin, levofloxacin, sparfloxacin, ofloxacin, ciprofloxacin, amikacin, clarithromycin에 대한 $MIC_{90}$은 각각 0.125, 0.39, 0.125, 1.0, 1.0, 15.6과 $1.56\;{\mu}g/ml$ 이었다. Erythromycin에만 저항성인 39균주의 $MIC_{90}$은 각각 0.06, 0.39, 0.125, 1.0, 1.0, 15.6과 $25.0\;{\mu}g/ml$ 이었다. Tetracycline과 erythromycin에 모두 저항성인 21 균주의 $MIC_{90}$은 각각 0.125, 0.39, 0.125, 1.0, 1.0, 3.9,과 $1.56\;{\mu}g/ml$ 이었다. Tetracycline과 erythromycin에 모두 감수성인 27 균주의 $MIC_{90}$은 각각 0.125, 0.39, 0.125, 1.0, 1.0, 7.8과 $0.09\;{\mu}g/ml$ 이었다. 이상의 결과로 moxifloxacin, levofloxacin, sparfloxacin 과 같은 quinolone 계 항생물질은 tetracycline이나 erythromycin에 단독 혹은 모두에 저항성인 M. pneumoniae 균주에도 감수성이었으므로 이들 균에 의한 감염증의 치료에 이용할 수 있는 약제이었으나, ofloxacin, ciprofloxacin, clarithromycin 등의 약제 선택에는 항생물질에 대한 감수성검사를 실시하여 적절한 항생제를 선택하는 등의 각별한 주의가 요망된다.

Keywords

References

  1. Arai, S., Y. Gohara, K. Kuwano, and T. Kawashima. 1992. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrobial Agents Chemother. 36, 1322-1324 https://doi.org/10.1128/AAC.36.6.1322
  2. Arai, S. and Y. Tokitsu. 1995. Antimycoplasmacidal activity of new quinolones in vitro and in vivo. Jap. J. Mycoplasmol. 21, 37-38
  3. Blanchard A., and C. Bebear. 2002. Mycoplasmas of human, pp 45-71, In Razin S, and Hermann R (ed), Molecular biology and pathogenicity of mycoplasma. Kluwer Academic Pub., New York
  4. Cassell, G. H., W. A. Clyde, and J. K. Davis. 1985. Mycoplasmal respiratory infections. pp. 65-106, In The Mycoplasmas Vol. IV, S. Razin and M. F. Barile (Ed), Academic Press, New York
  5. Chang M. W., K. H. Kim, I. D. Park, and M. H. Joh. 1995. Detection of Mycoplasma pneumoniae in clinical specimens of patients by polymerase chain reaction and culture method. J. Korean Soc. Microbiol. 30, 517-525
  6. Chang M. W., K. H. Kim, I. D. Park, K. H. Kang, E. H. Kong, M. H. Joh, G. Y. Song, and S. W. Kim. 2003. Rapid detection of Mycoplasma pneumoniae and antimicrobial susceptibilities of the M. pneumoniae isolates. J. Bacteriol. Virol. 33, 183-191
  7. Chang M. W., I. D. Park, K. H. Kim, G. Y. Song, and S. W. Kim. 2005. Tetracycline and erythromycin resistant mutans of the Mycoplasma pneumoniae isolated from patients with resipratory diseases. J. Life Sci. 15, 863-870 https://doi.org/10.5352/JLS.2005.15.6.863
  8. Chang M. W., K. H. Kim, I. D. Park, G. Y. Song, S. W. Kim, M. H. Joh, and C. E. Choi. 2005. Isolation of Mycoplasma pneumoniae and antimicrobial susceptibilities of the isolates(III). J. Life Sci. 15, 479-485 https://doi.org/10.5352/JLS.2005.15.3.479
  9. Critchley I. A., M. E. Jones, P. D. Heinze, D. Hubbard, H. D. Engler, A. T. Evangelista, C. Thornsberry, J. A. Karlowsky, and D. F. Sajm. 2002. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumonphila, Mycoplasma pneumoniae and Chlamydia pneumoniae from north America and Europe. Clin. Microbiol. Infect. 8, 214-221 https://doi.org/10.1046/j.1469-0691.2002.00392.x
  10. Duffy L. B., D. M. Crabb, X. Bing, and K. B. Waites. 2003. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J. Antimicrob. Chemother. 52, 527-528 https://doi.org/10.1093/jac/dkg365
  11. Ford O. K., and J. R. Smith. 1974. Nonspecific urethritis associated with a tetracycline- resistant T-mycoplasama. Br. J. Vener Dis. 50, 373-377
  12. Foy H., G. E. Kenny, M. K. Cooney, and I. D. Allen. 1979. Long-term epidemiology of infections with Mycoplasma pneumoniae. J. Infect. Dis. 139, 681-687 https://doi.org/10.1093/infdis/139.6.681
  13. Furneri, P. M., G. Rappazzo, M. P. Musumarra, P. Dipietro, L. S. Catania, and L. S. Roccasalva. 2001. Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of M. hominis. Antimicrob. Agents Chemother. 45, 2958-2960 https://doi.org/10.1128/AAC.45.10.2958-2960.2001
  14. Hamamoto K., T. Shimizu, N. Fujimoto, Y. Zhang, and S. Arai. 2001. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 4,: 1908-1910
  15. Hempstead P. G. 1990. An improved method for the rapid isolation of chromosomal DNA from Mycoplasma spp. Can. J. Microbiol. 36, 59-64 https://doi.org/10.1139/m90-011
  16. Izumikawa K., Y. Hirakata, T. Yamaguchi, R. Yoshida, H. Tanaka, H. Takemura, S. Maesaki, K. Tomono, M. Kaku, K. I. Izumikawa, S. Kamihira, and S. Kohono. 1998. In vitro activities of quinupristin-dalfopristin and the strteptogramin RPR 106972 against M. pneumoniae. Antimicrob. Agents Chemother. 42, 698-699
  17. Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, and et al. 1994. In vitro activities of sparfloxacin against M. pneumoniae. Antimicrob. Agents Chemother. 38, 738-741 https://doi.org/10.1128/AAC.38.4.738
  18. Kapusnik-Uner J. E., M. A. Sande, H. F. Chambers. 1996. Antimicrobial agents, tetracycline, chloramphenicol, erythromycin, and miscellaneous antimicrobial agents, pp1123-1153, In Goodman & Gilman,s The pharmacological basis of therapeutics, 9th(ed), McGraw-Hill, New York
  19. Kenny, G. E. and F. D. Cartwright. 1994. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to new glycycyclines in comparison with those to older tetracyclines. Antimicrob. Agents Chemother. 38, 2628-2632 https://doi.org/10.1128/AAC.38.11.2628
  20. Kenny, G. E. and F. D. Cartwright, 1996. Susceptibilities of M. pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to new quinolone, trovafloxacin(CP-99219). Antimicrob. Agents Chemother. 40, 1048-1049
  21. Krause D. C., and D. Taylor-Robinson. 1992. Mycoplasma which infect humans. pp417-444, In Maniloff J. (ed), Mycoplasmas, ASM, Washington
  22. Lucier, T. S., K. Heitzman, S. K. Liu, and P. C. Hu. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of M. pneumoniae. Antimicrob. Agents Chemother. 39, 2770-2773 https://doi.org/10.1128/AAC.39.12.2770
  23. MacGowan A. P. 1999. Moxifloxacin(Bay 12-8039): a new methoxy quinolone antibacterial. Expert. Opin. Investig. Drugs. 8, 181-199 https://doi.org/10.1517/13543784.8.2.181
  24. Matsuoka, M., M. Narita, N. Okazki, H. Ohya, T. Yamazaki, K. Ouchi, I. Suzuki, and T. Sasaki. 2004. Characterization and molecular analysis of macrolide- resistant M. pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48, 4624-4630 https://doi.org/10.1128/AAC.48.12.4624-4630.2004
  25. Morozumi M., K. Hasegawa, R. Kobayashi, N. Inoue, S. Iwata, H. Kuroki, N. Kawamura, E. Nakayama, T. Tajima, K. Shimizu, and K. Ubukata. 2005. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother. 49, 2302-2306 https://doi.org/10.1128/AAC.49.6.2302-2306.2005
  26. Niitu Y., S. Hasegawa , T. Suetake, H. Kubota, S. Komatu, and M. Horikawa. 1970. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr. 76, 434-443
  27. Okazaki, N., M. Narita, S. Yamada, K. Izumikawa, M. Umetsu, T. Kenri, Y. Sasaki, Y. Arakawa, and T. Sasaki. 2001. Characteristics of macrolide-resistant M. pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45, 617-620 https://doi.org/10.1111/j.1348-0421.2001.tb01293.x
  28. Park I. D., K. H. Kim, M. W. Chang, and H. S. Park. 1992. Distribution of tetM gene in the tetracycline resistant Bacteria. J. Korean Soc. Microbiol. 27, 59-72
  29. Pereyre, S., P. Gonzalez, B. de Barbeyrac, A. Darnige, H. Renaudin, A. Charron, S. Raherison, and C. M. Bebear, 2002. Mutation in 23S rRNA account for intrindic resistance to macrolides in M. hominis and M. fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob. Agents Chemother. 46, 3142-3150 https://doi.org/10.1128/AAC.46.10.3142-3150.2002
  30. Pereyre, S., C. Guyot, H. Renaudin, A. Charron, C. Bebear, and C. M. Bebear. 2004. In vitro selection and characterization of resistance to macrolides and related antibiotics in M. pneumoniae. Antimicrob. Agents Chemother. 48, 460-465 https://doi.org/10.1128/AAC.48.2.460-465.2004
  31. Roberts M. C., L. A. Koutsky, K. K. Holmes, D. J. LeBlanc, and G. E. Kenny. 1985. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob. Agents Chemother, 28, 141-143 https://doi.org/10.1128/AAC.28.1.141
  32. Shames J. M., R. B. George, W. B. Holliday, J. R. Rasch, and W. J. Mogabgab. 1970. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch. Intern. Med. 125, 680-684 https://doi.org/10.1001/archinte.125.4.680
  33. Smith R. P., A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp. 2004. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. Antimicrb. Agents Chemother. 48, 2081-2084 https://doi.org/10.1128/AAC.48.6.2081-2084.2004
  34. Suyama, N., K. Ishida, M. Kaku, K. Izumikawa, and K. Hara. 1995. Therapeutic activites of macrolides against M. pneumoniae infection. Jap. J. Mycoplasmol. 21, 39-40
  35. Vester, B. and S. Douthwaite. 2001. Macrolide resistance conferred by base substitution in 23S rRNA. Antimicrob. Agents Chemother. 45, 1-12 https://doi.org/10.1128/AAC.45.1.1-12.2001
  36. Waites, K. B., L. B. Duffy, T. Schmid, D. Carb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, M. hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35, 1181-1185 https://doi.org/10.1128/AAC.35.6.1181
  37. Waites K. B., D. M. Crabb, and L. B. Duffy. 2003. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int. J. Antimicrob. Agents. 21, 574-577 https://doi.org/10.1016/S0924-8579(03)00060-8
  38. Waites K. B., D. M. Crabb, X. Bing, and L. B. Duffy. 2003. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobials against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47, 161-165 https://doi.org/10.1128/AAC.47.1.161-165.2003
  39. Waites K. B., D. M. Crabb, and L. B. Duffy. 2003. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob. Agents Chemother. 47, 39-42 https://doi.org/10.1128/AAC.47.1.39-42.2003
  40. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39, 577-585 https://doi.org/10.1128/AAC.39.3.577
  41. Yamaguchi, T., Y. Hirakata, K. Izumikawa, Y. Miyazaki, S. Maesaki, K. Tomono, Y. Yamada, S. Kamihira, and S. Kohno. 2000. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of M. pneumoniae in Japan. Antimicrob. Agents chemother. 44, 1381-1382 https://doi.org/10.1128/AAC.44.5.1381-1382.2000